Study S000012

Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of NNC0480-0389 in Combination With Semaglutide s.c.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04259801
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 152
Start: 2020-02-17
Primary completion: 2022-03-16
Lead sponsor: Novo Nordisk A/S
Conditions: Healthy Volunteers; Overweight; Obesity; Diabetes Mellitus, Type 2
Interventions: DRUG:NNC0480-0389; DRUG:Semaglutide; DRUG:Placebo (NNC0480-0389); DRUG:Placebo (semaglutide)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:2019-002857-44; OTHER:U1111-1236-4114; NIH:2019

Registered primary outcomes

Number of treatment emergent adverse events (TEAE) in Part 1 [From time of dosing (day 1) until completion of follow-up visit (day 71)]
Number of treatment emergent adverse events (TEAE) in Part 2 [From first combination dosing (day 57) until completion of follow-up visit (day 148)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.